<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80568">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01857947</url>
  </required_header>
  <id_info>
    <org_study_id>UTAPE01</org_study_id>
    <nct_id>NCT01857947</nct_id>
  </id_info>
  <brief_title>Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER</brief_title>
  <acronym>UTAPE BPCO</acronym>
  <official_title>Usefulness of Pro-adrenomedullin (MR proADM)as a Predictor of Outcome in Acute Exacerbations of COPD Visiting the Emergency Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThermoFisher Scientific Brahms Biomarkers France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ThermoFisher Scientific Brahms Biomarkers France</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition
      to clinical evaluation is effective to predict outcome of acute exacerbations of COPD
      patients visiting the emergency room(ER).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute exacerbation of COPD (AECOPD)are usual and frequent cause of admission in emergency
      room (ER). No validated clinical or biological predictor of evolution are available.

      The main objective is to determine the prognosis value of Mr proADM in addition to the
      clinical risk stratification for AE COPD patients in ER.

      Patients presenting with a AECOPD diagnosis in ER will have a blood sample collected and
      freezed at their admission. Mr proADM will be assessed at the end of the study. Clinicians
      in charge of patients will not have the result during the management of their patients. This
      study implies no change in the patients' management.

      Data related to the patients'demographic,current exacerbation and basic COPD characteristics
      will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>composite outcome measure</measure>
    <time_frame>at Day 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death, subsequently transfer to ICU, relapse, need to be ventilated after 24 hours of their admission in ER</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite outcome</measure>
    <time_frame>at Day 7 of ER admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death, subsequently transfer to ICU, relapse, need to be ventilated after 24 hours of their admission in ER</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between Mr proADM and patients Severity</measure>
    <time_frame>at Day 7 and Day 30 of ED admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation between MR proADM and patient's severity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>COPD Patients Admitted in ER for Acute Exacerbation</condition>
  <arm_group>
    <arm_group_label>AECOPD Mr proADM</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AECOPD Mr proADM</intervention_name>
    <arm_group_label>AECOPD Mr proADM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &gt; 40 years old

          -  Acute exacerbation of COPD

        Exclusion Criteria:

          -  Medico social conditions not allowing home discharge

          -  Other causes of Dyspnea: Pneumothorax, pulmonary embolism, pulmonary oedema, lung
             cancer

          -  Pneumonia on chest ray

          -  acute respiratory distress requiring immediate ICU transfer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Roche, MD PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Hotel Dieu Hospital Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Dres, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hopital Bicêtre Le Krémlin Bicêtre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Hausfater, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié Salpétrière Hospital Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Plaisance, Pr MD</last_name>
    <phone>+331 49956391</phone>
    <email>patrick.plaisance@lrb.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Plaisance, MD PHD</last_name>
      <phone>+33149956391</phone>
      <email>patrick.plaisance@lrb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Plaisance, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pitié Salpétrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Hausfater, MD PHD</last_name>
      <phone>+33142177240</phone>
      <email>pierre.hausfater@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Hausfater, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 17, 2013</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AECOPD Mr ProADM Biomarkers ER Outcome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenomedullin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
